No Cover Image

Journal article 22776 views

Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry

J. Wagstaff, R. Jones, R. Hawkins, E. Porfiri, L. Pickering, A. Bahl, J. Brown, S. Buchan, John Wagstaff

Annals of Oncology, Volume: 27, Issue: 1, Pages: 159 - 165

Swansea University Author: John Wagstaff

Full text not available from this repository: check for access using links below.

DOI (Published version): 10.1093/annonc/mdv504

Abstract

The aim of the RECORD registry was to collect real world data on the outcomes for patients with locally advanced inoperable renal cell carcinoma (RCC) treated with modern targeted therapies. Individual patient data were collected from consecutive patients in one Welsh, one Scottish and five English...

Full description

Published in: Annals of Oncology
Published: 2015
URI: https://cronfa.swan.ac.uk/Record/cronfa25006
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2015-12-10T01:57:47Z
last_indexed 2019-07-16T20:27:58Z
id cronfa25006
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2019-07-16T10:44:27.9949657</datestamp><bib-version>v2</bib-version><id>25006</id><entry>2015-12-09</entry><title>Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry</title><swanseaauthors><author><sid>fdab5e9e2fe06c93d3ffa19c816bdcf6</sid><firstname>John</firstname><surname>Wagstaff</surname><name>John Wagstaff</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2015-12-09</date><deptcode>SGMED</deptcode><abstract>The aim of the RECORD registry was to collect real world data on the outcomes for patients with locally advanced inoperable renal cell carcinoma (RCC) treated with modern targeted therapies. Individual patient data were collected from consecutive patients in one Welsh, one Scottish and five English Cancer Centres that treated patients with locally advanced and metastatic RCC. Data from 514 patients were collected between March 2009 and November 2012. Median overall survival (OS) was 23.9 months from the initiation of first line treatment. This is similar to the median OS found in the pivotal registration trials of sunitinib and pazopanib which are the main first line treatments in this disease.Median OS was significantly longer for those patients receiving second line treatment (33 months) compared with those who did not (20.9 months; p=0.008). These data confirm that results in the real world are comparable to results obtained in prospective clinical trials. The data also emphasise the importance of second line therapy in obtaining optimum survival.</abstract><type>Journal Article</type><journal>Annals of Oncology</journal><volume>27</volume><journalNumber>1</journalNumber><paginationStart>159</paginationStart><paginationEnd>165</paginationEnd><publisher/><keywords>Renal Cell Carcinoma, survival, pazopanib, sunitinib</keywords><publishedDay>21</publishedDay><publishedMonth>10</publishedMonth><publishedYear>2015</publishedYear><publishedDate>2015-10-21</publishedDate><doi>10.1093/annonc/mdv504</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School - School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>SGMED</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2019-07-16T10:44:27.9949657</lastEdited><Created>2015-12-09T16:45:42.3671065</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>J.</firstname><surname>Wagstaff</surname><order>1</order></author><author><firstname>R.</firstname><surname>Jones</surname><order>2</order></author><author><firstname>R.</firstname><surname>Hawkins</surname><order>3</order></author><author><firstname>E.</firstname><surname>Porfiri</surname><order>4</order></author><author><firstname>L.</firstname><surname>Pickering</surname><order>5</order></author><author><firstname>A.</firstname><surname>Bahl</surname><order>6</order></author><author><firstname>J.</firstname><surname>Brown</surname><order>7</order></author><author><firstname>S.</firstname><surname>Buchan</surname><order>8</order></author><author><firstname>John</firstname><surname>Wagstaff</surname><order>9</order></author></authors><documents/><OutputDurs/></rfc1807>
spelling 2019-07-16T10:44:27.9949657 v2 25006 2015-12-09 Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry fdab5e9e2fe06c93d3ffa19c816bdcf6 John Wagstaff John Wagstaff true false 2015-12-09 SGMED The aim of the RECORD registry was to collect real world data on the outcomes for patients with locally advanced inoperable renal cell carcinoma (RCC) treated with modern targeted therapies. Individual patient data were collected from consecutive patients in one Welsh, one Scottish and five English Cancer Centres that treated patients with locally advanced and metastatic RCC. Data from 514 patients were collected between March 2009 and November 2012. Median overall survival (OS) was 23.9 months from the initiation of first line treatment. This is similar to the median OS found in the pivotal registration trials of sunitinib and pazopanib which are the main first line treatments in this disease.Median OS was significantly longer for those patients receiving second line treatment (33 months) compared with those who did not (20.9 months; p=0.008). These data confirm that results in the real world are comparable to results obtained in prospective clinical trials. The data also emphasise the importance of second line therapy in obtaining optimum survival. Journal Article Annals of Oncology 27 1 159 165 Renal Cell Carcinoma, survival, pazopanib, sunitinib 21 10 2015 2015-10-21 10.1093/annonc/mdv504 COLLEGE NANME Medical School - School COLLEGE CODE SGMED Swansea University 2019-07-16T10:44:27.9949657 2015-12-09T16:45:42.3671065 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine J. Wagstaff 1 R. Jones 2 R. Hawkins 3 E. Porfiri 4 L. Pickering 5 A. Bahl 6 J. Brown 7 S. Buchan 8 John Wagstaff 9
title Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry
spellingShingle Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry
John Wagstaff
title_short Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry
title_full Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry
title_fullStr Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry
title_full_unstemmed Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry
title_sort Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry
author_id_str_mv fdab5e9e2fe06c93d3ffa19c816bdcf6
author_id_fullname_str_mv fdab5e9e2fe06c93d3ffa19c816bdcf6_***_John Wagstaff
author John Wagstaff
author2 J. Wagstaff
R. Jones
R. Hawkins
E. Porfiri
L. Pickering
A. Bahl
J. Brown
S. Buchan
John Wagstaff
format Journal article
container_title Annals of Oncology
container_volume 27
container_issue 1
container_start_page 159
publishDate 2015
institution Swansea University
doi_str_mv 10.1093/annonc/mdv504
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 0
active_str 0
description The aim of the RECORD registry was to collect real world data on the outcomes for patients with locally advanced inoperable renal cell carcinoma (RCC) treated with modern targeted therapies. Individual patient data were collected from consecutive patients in one Welsh, one Scottish and five English Cancer Centres that treated patients with locally advanced and metastatic RCC. Data from 514 patients were collected between March 2009 and November 2012. Median overall survival (OS) was 23.9 months from the initiation of first line treatment. This is similar to the median OS found in the pivotal registration trials of sunitinib and pazopanib which are the main first line treatments in this disease.Median OS was significantly longer for those patients receiving second line treatment (33 months) compared with those who did not (20.9 months; p=0.008). These data confirm that results in the real world are comparable to results obtained in prospective clinical trials. The data also emphasise the importance of second line therapy in obtaining optimum survival.
published_date 2015-10-21T03:29:44Z
_version_ 1763751162323927040
score 11.037603

Similar Items